Each drug is competing for a site and the Dilantin may be unable to locate a

Each drug is competing for a site and the dilantin

This preview shows page 14 - 15 out of 15 pages.

binding sites to start with. Each drug is competing for a site, and the Dilantin may be unable to locate a binding site. Therefore, the effects of the Dilantin therapy will increase because more free or unbound drug is available to be active. Dilantin is a highly protein-bound drug and less creatinine is available overall to be filtered. Age-related changes in the central nervous system affectthe efficiency of the blood–brain barrier, not the drug itself.Question 40 1 out of 1 pointsA 79-year-old woman has been admitted to the hospital with a gastrointestinal bleed. She is currently receiving a transfusion of packed red blood cells as well as an infusion of pantoprazole (Protonix), a proton-pump inhibitor, to help stop her bleeding. What care settingis most appropriate for this patient?Response Feedback: Blood transfusions and continuous infusions of intravenous medications require the vigilant assessment and monitoring that can be provided in an acute care setting; this is not normally possible in an ARU or transitional care setting and would be impossible in an outpatient environment.Question 41 0 out of 0 pointsWhen completing this quiz, did you comply with Walden University’s Code of Conduct including the expectations for academic integrity?
Image of page 14
Saturday, September 1, 2018 7:38:13 PM EDT
Image of page 15

You've reached the end of your free preview.

Want to read all 15 pages?

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture